Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Operating Leases (2019 - 2025)

Heron Therapeutics filings provide 7 years of Operating Leases readings, the most recent being $780000.0 for Q3 2025.

  • On a quarterly basis, Operating Leases rose 49.43% to $780000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $780000.0, a 49.43% increase, with the full-year FY2023 number at $2.8 million, down 49.08% from a year prior.
  • Operating Leases hit $780000.0 in Q3 2025 for Heron Therapeutics, down from $1.5 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $13.8 million in Q1 2021 to a low of $522000.0 in Q3 2024.
  • Median Operating Leases over the past 5 years was $4.8 million (2023), compared with a mean of $5.5 million.
  • Biggest five-year swings in Operating Leases: crashed 85.24% in 2024 and later surged 49.43% in 2025.
  • Heron Therapeutics' Operating Leases stood at $8.0 million in 2021, then crashed by 31.23% to $5.5 million in 2022, then plummeted by 49.08% to $2.8 million in 2023, then tumbled by 81.36% to $522000.0 in 2024, then surged by 49.43% to $780000.0 in 2025.
  • The last three reported values for Operating Leases were $780000.0 (Q3 2025), $1.5 million (Q2 2025), and $522000.0 (Q3 2024) per Business Quant data.